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Abstract: The aim of this study was to evaluate whether genome-wide levels of DNA 
methylation are associated with age and the health risks of obesity (HRO); defined 
according to BMI categories as “Low HRO” (overweight and class 1 obesity) versus  
“High HRO” (class 2 and class 3 obesity). Anthropometric measurements were assessed in 
a subsample of 48 volunteers from the Metabolic Syndrome Reduction in Navarra 
(RESMENA) study and 24 women from another independent study, Effects of Lipoic Acid 
and Eicosapentaenoic Acid in Human Obesity (OBEPALIP study). In the pooled population; 
the methylation levels of 55 CpG sites were significantly associated with age after 
Benjamini-Hochberg correction. In addition, DNA methylation of three CpG sites located 
in ELOVL2; HOXC4 and PI4KB were further negatively associated with their mRNA 
levels. Although no differentially methylated CpG sites were identified in relation to HRO 
after multiple testing correction; several nominally significant CpG sites were identified in 
genes related to insulin signaling; energy and lipid metabolism. Moreover, statistically 
significant associations between BMI or mRNA levels and two HRO-related CpG sites 
located in GPR133 and ITGB5 are reported. As a conclusion, these findings from two 
Spanish cohorts add knowledge about the important role of DNA methylation in the  
age-related regulation of gene expression. In addition; a relevant influence of age on DNA 
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methylation in white blood cells was found, as well as, on a trend level, novel associations 
between DNA methylation and obesity. 
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1. Introduction 
Obesity plays a crucial role in metabolic syndrome features onset, and it has been defined as  
a chronic disease associated with important cardiorespiratory and cardiometabolic risks [1]. The 
predisposition to gain excessive weight and develop obesity as a result of the intake of energy-rich 
diets is partly controlled by specific genes [2]. In some studies, between 40% and 70% of the body 
weight variability has been attributed to genetic inheritance, being the number of associated genes 
continuously increasing due to Genome-Wide Association Studies (GWAS) [3]. The increase in 
obesity prevalence may also be the result of epigenetic changes [4,5]. Epigenetics studies the 
inheritable and reversible phenomena that affect gene expression without altering the underlying base 
pair sequence [6]. Thus, the same nucleotide sequence in two individuals can be differently expressed 
or not depending on specific epigenetic marks [7]. 
DNA methylation occurs preferentially in sequences whose pattern is a cytosine followed by a 
guanine residue, called CpG dinucleotides. These CpG sites are especially common in the promoter 
regions of many genes and, when methylated, tend to be associated with gene silencing [8]. These 
epigenetic marks are not permanent over time and many factors, such as nutrition, inflammation, 
physical activities, oxidative stress, hypoxia, smoking, sex or age, induce changes in the epigenome, 
contributing to its plasticity throughout life [9,10]. 
Several studies have also shown that changes in the epigenome vary during the different life cycle 
stages [11,12]. Thus, it has been reported that epigenetic marks at the early age are responsible for 
controlling gene expression during adulthood [13]. In this sense, different epigenetic patterns associated 
with aging seem to occur, which are related to changes in regulatory gene expression and metabolic 
functions. Aging could lead to genome-wide demethylation in certain gene coding regions [14], 
although, more often, aging has been related to increased methylation of certain CpGs in specific gene 
families, CpG islands [15] and bivalent chromatin domains [16]. These epigenetic modifications could 
be implicated in the onset of cancer and other diseases associated with advancing age, and also appear 
to depend on the gene and tissue analyzed. For example, studies in liver and visceral adipose tissue 
have revealed differences in DNA methylation with age at >5% of sites analyzed (from a total of one 
thousand randomly selected loci), many of them near genes that are involved in metabolic regulation, 
suggesting a potential role in the pathogenesis of age-related diseases [17]. 
Moreover, obesity is not only an aesthetic problem due to inadequate dietary and sedentary lifestyle 
habits, since excessive fat accumulation greatly raises the risk for other health problems, such  
as coronary heart disease, type 2 diabetes, hypertension, metabolic syndrome or reproductive  
problems [18]. All these complications are included under the name of health risk of obesity (HRO). 
The National Institutes of Health guidelines indicate that the HRO increases in a graded fashion when 
moving from the normal-weight through obese BMI categories [19]. In addition to a predisposing 
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genetic makeup to easier weight gain and fat deposition, a lot of recognized scientific evidence has 
theorized about the roles of other putative determinants. Several investigations aiming to understand 
energy metabolism have been performed considering the potential involvement of epigenetics and 
perinatal programming [13,20,21]. Indeed, inheritance-oriented investigations concerning gene-nutrient 
interactions on energy homeostasis processes and metabolic cell functions are extending to all 
clinically chronic relevant diseases, such as type 2 diabetes, cardiovascular events, obesity and 
associated features of metabolic syndrome. 
The aim of this study was to evaluate whether genome-wide levels of DNA methylation in white 
blood cells are associated with age and the HRO, defined as the risk of obesity-related health 
problems, in two unrelated Spanish cohorts. 
2. Results and Discussion 
We have conducted a pilot study to examine the associations between DNA methylation and age,  
as well as HRO, in order to better understand epigenetic contributions to health in two Spanish 
populations, where these associations, to our knowledge, have not yet been examined. 
A total of 73 participants, 35.6% men, were suitable for the analysis. The general features of 
subjects grouped by study are shown in Table 1. As expected, the “High HRO” group evidenced 
greater levels (p < 0.05) of body weight, BMI and waist circumference than the “Low HRO” group 
(Table 1). Age and anthropometric measurements were significantly lower in the “Effects of Lipoic Acid 
and Eicosapentaenoic Acid (EPA) in Human Obesity” (OBEPALIP) population compared with the 
Metabolic Syndrome Reduction in Navarra (RESMENA) study (p-value < 0.001). These two cohorts 
differed in the inclusion criteria. The OBEPALIP study recruited only women without metabolic 
syndrome from 20 to 45 years old, while the RESMENA study had broader criteria (both genders  
aged between 35 and 70 years old with a high prevalence of metabolic syndrome). Moreover, 
anthropometric differences between the two populations were mainly due to age, the presence of 
metabolic syndrome and gender. Women from OBEPALIP study could be considered more 
metabolically healthy overweight and obese subjects (without other complications), while most 
subjects from RESMENA population had metabolic syndrome (81%). Metabolically healthy obese 
individuals display less visceral adipose tissue, smaller adipocytes, and a reduced inflammatory profile 
when compared with metabolically unhealthy obese individuals [22]. Healthy obese subjects are also 
at a lower risk thereof than individuals who are both unhealthy and obese [23]. The relatively low risk 
of cardiovascular disease among metabolically healthy people with respect to unhealthy obese people 
has been attributed to differences in white adipose tissue function between both groups of patients [24]. 
Table 1. General characteristics of the studied subjects. 
Variables 
Pooled Population RESMENA Study OBEPALIP Study 
TP LR HR TP LR HR TP LR HR 
n 73 40 33 48 18 30 25 22 3 
Age (year) 45 (10) 41 (10) 49 (10) + 48 (10) 47 (10) 49 (10) 37 (7) * 37 (8) 42 (2) 
Sex (M/F) 26/47 9/31 17/16 + 26/22 9/9 17/13 0/25 0/22 0/3 
Weight  
(Kg) 
95.5 
(17.8) 
85.8 
(10.4) 
107.0 
(18.0) + 
102.4 
(17.9) 
90.5 
(11.6) 
109.1 
(17.4) + 
82.7 
(7.6) * 
82.3 
(7.9) 
86.0 
(4.0) 
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Table 1. Cont. 
Variables 
Pooled Population RESMENA Study OBEPALIP Study 
TP LR HR TP LR HR TP LR HR 
BMI  
(kg/m2) 
34.6 
(4.1) 
31.5 
(2.3) 
38.1 
(2.7) + 
36.2 
(3.8) 
32.4 
(2.7) 
38.2 
(3.8) + 
31.5 
(2.7) * 
30.9 
(2.3) 
36.0 
(0.6) + 
WC  
(cm) 
106.0 
(13.4) 
98.1 
(8.8) 
115.3 
(11.9) + 
112.0 
(12.5) 
102.5 
(10.2) 
117.3 
(10.5) + 
94.7 
(5.7) * 
94.6 
(5.8) 
95.3 
(5.7) 
Metabolic Syndrome 1 39 12 27 39 12 27 0 * 0 0 
Smoking 12 7 5 8 3 5 4 4 0 
Data are expressed as mean (standard deviation). Abbreviations: TP, total population; LR, Low HRO;  
HR, High HRO; n, number of subjects; BMI, body mass index; WC, waist circumference; 1 The metabolic 
syndrome was diagnosed following the ATP III criteria; * Significant differences between the two 
populations, p-value < 0.001; + Significant differences between low and high HRO, p-value < 0.05. 
2.1. Identification of CpG Sites Differentially Methylated with Age in WBC 
In this study, the white blood cell (WBC) DNA methylation profile was analyzed in 73 subjects  
using Illumina Infinium HumanMethylation450 BeadChip (Illumina, San Diego, CA, USA). The age 
range was 21–58 years old. Linear regression analysis identified 54 CpG sites associated with age  
(Table S1). The top 8 significant loci located within or nearby to the CpG islands of ELOVL2,  
PRLHR, PI4KB, MFSD5, HOXC4, ZEB2 and FHL2 genes had the smallest p-value below the 
Benjamini-Hochberg threshold (≤0.05) adjusted for gender, smoking, metabolic syndrome, the 
research group that made each study, T cell (CD8+), T cell (CD4+), B cells and random batch effect 
(Figure 1a). The same CpGs showed the highest Spearman’s coefficients (Figure 1b) between DNA 
methylation levels and age in the WBC from the pooled population and in the two independent 
populations (RESMENA and OBEPALIP studies). The patterns of results in both cohorts were 
comparable (the correlation coefficients describe the same direction (positive or negative) and statistical 
significance at raw p-value <0.01). Moreover, the possible interaction effects between cohorts and age 
on DNA methylation levels that represent the combined effects of factors on the dependent measure 
were tested. No interaction effects were found. Thus, the impact of age and methylation is independent 
of the cohorts. 
DNA methylation is well known to change during aging [25]. Recent studies have demonstrated the 
presence of age-related CpG sites, which are characterized by a global loss of DNA methylation during 
aging [26]. However, some genes become hypermethylated with age [26]. The methylation levels of 
the CpG sites of ELOVL2, PRLHR, HOXC4, and FHL2 positively correlated with age. In this sense, 
DNA methylation levels could be used to estimate age [27]. Biological clocks, such as the epigenetic 
clock, are promising biomarkers of aging [28]. However, this pilot research requires further studies to 
replicate the age-related associations and find the predictive value of the estimate age. 
Increased DNA methylation of certain genomic regions may be involved in the silencing of gene 
transcription [29]. Therefore, it was tested if these selected CpG sites with increased DNA methylation 
were associated with decreased mRNA expression of genes located near the CpG sites in the 
RESMENA cohort. The DNA methylation levels of three of the selected CpG sites (cg16867657, 
cg01974375 and cg18473521) showed a statistically significant negative correlation with the mRNA 
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levels of the respective genes (ELOV2, PI4KB and HOXC4) in the same cells (WBC) of the screened 
subjects (Figure 1c). 
The methylation levels of CpG sites located in genes like ELOVL2 and FHL2, have been  
strongly correlated with age in previous genome-wide methylation studies [30,31]. ELOVL2 encodes a 
transmembrane protein involved in the synthesis of long ω3- and ω6-polyunsaturated fatty acids  
(PUFA) [32]. Considering that PUFAs are involved in crucial biological functions including energy 
production, inflammation, and maintenance of cell membrane integrity, it is possible that ELOVL2 
methylation plays a role in the aging process through the regulation of different biological pathways. 
 
Figure 1. Associations between age and DNA methylation in different CpGs. (a) Manhattan 
plot of genome-wide p-values from the pooled population; (b) Adjusted p-values and 
Spearman correlation coefficients of the selected CpG sites with respect to age. CpGs are 
ranked by adjusted p-value, from smallest to largest. The number of subjects included in the 
pooled population, RESMENA study and OBEPALIP, were 73, 48 and 25, respectively.  
1 p-value of age-cohort interaction analyzed with a linear regression. * denotes statistical 
significance at adjusted p-value < 0.05; + denotes statistical significance at raw p-value < 0.01; 
(c) Graphical representation of the correlation between DNA methylation levels of the selected 
CpG sites and mRNA expression of the respective genes in RESMENA study (n = 24). Data 
are presented as linear regression (solid straight line) graph and 95% confidence interval 
(dotted lines). Localization: Chromosome on which the target locus is located and genomic 
position of C in the CpG dinucleotide; RefGene Group: Gene region feature category; 
adj.P.Val: adjusted p-value for multiple testing. 
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By using a linear mixed model in a transcriptomic approach, the gene expression of MFSD5 in skin 
was associated with age [33]. MFSD5 (major facilitator superfamily domain containing 5) encodes a 
protein that facilitates the transport across cytoplasmic or internal membranes of molybdate anion. 
However, the age-related mechanism that affects the expression of this gene remains to be elucidated. 
A CpG site of HOXC4 was significantly associated with age. HOXC4 is a member of the homeobox 
(HOX) family of master transcription factors crucial in morphogenesis and development [34].  
The expression of many HOX genes, including HOXC4, declines with age, even prior to adulthood [35]. 
An association of HOX genes with longevity has been proposed [36], although there is not direct 
evidence so far linking HOXC4 to human aging. ZEB2 is another age-associated gene. This gene (also 
known as SIP1) is a member of the Zfh1 family of 2-handed zinc finger/homeodomain proteins. Its 
relevance to tumor progression has been studied in several forms of human cancer [37], although the 
association of ZEB2 with age has not been previously reported. Lastly, phosphatidylinositol 4-kinase 
beta (PI4KB) is a soluble enzyme shuttling between the cytoplasm and the nucleus, which regulates 
the trafficking from the Golgi system to the plasma membrane [38]. Although this gene has been 
recently described as a candidate age-associated genomic region [39], its involvement in aging is  
still unclear. 
The Gene Ontology (GO) analysis of these CpG sites differentially methylated with age showed 
processes related to apoptosis, signal transduction and transcriptional regulation, rhythmic process, 
DNA repair and chromatin remodeling, cell differentiation or metabolic processes. However, no 
significant terms were found in GO enrichment analysis. 
2.2. Identification of CpG Sites Differentially Methylated in Relation to the Health Risks of Obesity (HRO) 
We identified 85 CpG sites (Figure 2a) differentially methylated (mean absolute methylation 
difference ≥ 10%; raw p-value < 0.01) between “Low HRO” (overweight and class 1 obesity) and “High 
HRO” (class 2 and 3 obesity). However, none of these CpGs remained statistically significant after 
Benjamini-Hochberg correction. Forty-one CpG sites were hypomethylated and 44 hypermethylated in 
the “Low HRO” group compared to the “High HRO” group (Table S2), as shown in the Volcano plot 
(Figure 2a). The GO analysis revealed that the genomic regions where these differentially methylated 
CpG sites are located have been involved in different processes related to apoptosis, transcriptional 
regulation and inflammatory response, cell cycle, oxidative stress response, energy reserve metabolic 
processes, insulin receptor signaling pathway and carbohydrate and lipid metabolic processes (Table S2). 
Eight CpG sites (Figure 2b) were selected for further demonstrating whether the changes in DNA 
methylation were accompanied by changes in gene expression. The selection of these CpG sites was 
based on two conditions: the methylation differences between “Low HRO” and “High HRO” were ≥10% 
and p-value ≤0.01, and previous reports associating these genes with obesity [40–47]. The patterns of 
results in both cohorts were comparable in most of the selected CpG sites (the same size effect 
direction (positive or negative) and statistical significance at raw p-value <0.01). The possible 
interaction effects between cohorts and HRO on DNA methylation levels were also tested. No interaction 
effects were found. Thus, the impact of HRO and methylation is independent of the cohorts. 
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(a) 
(b) 
Figure 2. Identification of CpGs and genes differentially methylated between “Low HRO” 
and “High HRO” subjects. (a) Volcano plot of the 358,639 CpG sites of raw p-values log 
versus mean methylation differences (effect size) comparing Low HRO group to High 
HRO groups. Hypermethylation means more methylation in the Low HRO group 
compared to the High HRO group, and hypomethylation refers to less methylation in the 
Low HRO group than in the High HRO group. CpG sites hypermethylated (n = 44) and 
hypomethylated (n = 41) are shown in black; CpG sites that were not differentially 
methylated (raw p-value > 0.01) are shown in grey; (b) p-values and effect size of the 
selected CpG sites between groups. CpGs are ranked by p-value, from smallest to largest.  
1 p-value of HRO-cohort interaction analyzed with ANOVA. +, denotes statistical 
significance at raw p-value < 0.01. 
The expression analysis of these selected genes identified that the DNA methylation levels at CpG 
sites measured by the probes cg21046080 and cg18770216 were negatively correlated with the expression 
of GPR133 and ITGB5, respectively, in WBC from the RESMENA cohort (n = 24) (Figure 3). 
Moreover, a linear regression model was used to analyze the potential associations in relation to 
each domain of variables (DNA methylation, age, gender, smoking, metabolic syndrome, the research 
Illumina ID 
Gene 
Name 
Localization 
RefGene 
Group 
P.Val 
Size Effect (%)
P.Val 
Interaction 1 
Pooled 
Population
RESMENA 
Study 
OBEPALI
P Study 
cg15445000 MED1 17:37608096 TSS1500 4.62 × 10−4 13.43+ 13.79+ 10.36 0.362 
cg26008260 ADCY3 2:25057298 Body 5.50 × 10−4 12.52+ 6.01 19.25+ 0.727 
cg18269141 PRKCZ 1:2063966 5′UTR 1.00 × 10−3 13.05+ 14.74+ 7.85 0.351 
cg21046080 GPR133 12:131506092 Body 1.96 × 10−3 −25.61+ −20.26+ −48.49+ 0.650 
cg18770216 ITGB5 3:124491657 Body 4.36 × 10−3 −12.82+ −7.13+ −22.60+ 0.451 
cg26303777 GALNT2 1:230311676 Body 4.89 × 10−3 15.79+ 11.28+ 30.51+ 0.427 
cg21473814 CRTC1 19:18873268 Body 4.98 × 10−3 −10.77+ −8.53+ −18.69+ 0.361 
cg02697649 FZD7 2:202901045 1stExon 6.76 × 10−3 15.34+ 11.43+ 32.02+ 0.558
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group that made each study and batch effect) and BMI as dependent variable in the pooled population 
(n = 73). Thus, the predictors of the model (metabolic syndrome and DNA methylation levels) 
explained up to 40% of the variation of the BMI in the case of cg18269141. This CpG is located in 
PRKCZ gene, a gene with a potential role in obesity and/or related traits [41]. The PRKCZ methylation 
in human adipose tissue is modified after gastric bypass and weight loss [41] and the hypermethylation 
of this gene may be involved in the pathogenesis of type 2 diabetes [48] (Table 2). 
 
Figure 3. Associations between CpG sites that exhibit differential DNA methylation 
between the HRO groups and the expression levels of their respective genes in WBC from 
the RESMENA cohort. Data are presented as linear regression (solid straight line) graph 
and 95% confidence interval (dotted lines). (a) cg21046080 and GPR133; (b) cg18770216 
and ITGB5. 
Table 2. Lineal regression analyses showing the contribution of DNA methylation to the 
variation of BMI adjusted by age, gender, smoking, metabolic syndrome, the research 
group that made each study, and batch effect in the pooled population (n = 73). 
BMI as Dependent 
Standardized 
Beta Coefficient 
Unstandardized B 
Coefficient (95% CI) 
p-Value a R2 
cg15445000_MED1 −0.249 −6.61 (−11.78; −1.43) 0.013 0.335 
cg26008260_ADCY3 −0.332 −103.66 (−168.75; −38.6) 0.002 0.349 
cg18269141_PRKCZ −0.356 −8.73 (−13.68; −3.78) 0.003 0.397 
cg21046080_GPR133 0.278 5.11 (1.68; 10.01) 0.017 0.292 
cg18770216_ITGB5 0.211 5.26 (0.21; 10.31) 0.041 0.299 
cg26303777_GALNT2 0.122 2.61 (−1.91; 7.11) 0.252 0.360 
cg21473814_CRTC1 −0.039 −1.13 (−7.28; 5.20) 0.771 0.270 
cg02697649_FZD7 −0.103 −2.08 (−6.21; 2.05) 0.318 0.279 
Adjusted R2 and all independent variables included in each model are presented in the table; Bold and italic 
style show statistically significant p-values; a p-value of Beta coefficient for DNA methylation levels;  
CI: Confidence interval. 
DNA methylation is an epigenetic event implicated in several human diseases by altering gene 
expression [49], these processes being suggested as a potential contributing factor to cancer risk [50]. 
Recent researches have shown that differential variability in methylation is also an important feature  
of obesity [51] and, for example, some genes have been revealed to be hypermethylated in lean 
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compared with obese subjects [52]. On the other hand, the methylation of specific genomic regions 
could be related to the response to a weight loss intervention, both in obese adults [4,53,54] and in 
adolescents [55]. Concerning the metabolic complications of obesity, it has been recently reported  
that the leukocyte methylome is altered in obesity associated with metabolic disturbances, including 
differences in 23 genes known to be associated with obesity, liver fat, type 2 diabetes and metabolic 
syndrome [56]. Moreover, platelet mitochondrial DNA methylation has been recently related to 
cardiovascular risk, although not with BMI [57]. 
In our study, we have described significant correlations between BMI and the methylation levels of 
five CpGs, which may explain some of the BMI variation observed in our studied population. In 
addition, we have found negative correlations between the methylation of two CpG sites (cg21046080 
and cg18770216) and the mRNA levels of the respective genes (GPR133 and ITGB5) in WBC of the 
RESMENA study. Existing data are consistent with a role for these genes in body weight regulation. 
They are specifically expressed in glands that hormonally are involved in the control of body  
weight and fat (GPR133 in adrenal glands) [40] or are up-regulated in obese children (ITGB5) [42].  
Henegar et al. [58] also reported that ITGB5 and other genes encoding the members of the integrin 
family were significantly induced and co-expressed in adipose tissue from obese adults. 
Our study has certain limitations. First, since the nature of this study is cross-sectional, we can only 
report associations between age/HRO and DNA methylation even if controlling for several potential 
covariates but not a causal relationship. Another limitation of this study is that, although the sample 
size is adequate from the standpoint of an initial association discovery, further replications would be 
needed in independent and larger samples. Furthermore, no blood cell count was carried out, resulting 
in a possible limitation in the interpretation of DNA methylation levels due to the influence of the 
tissue heterogeneity in epigenetic studies related to age and obesity [27,59]. Nevertheless, one of the 
aims of the present work was to use WBC as a source of easily isolated biomarkers of HRO, as other 
studies have previously reported [54,60]. Moreover, we performed an additional analysis to estimate 
the variation explained due to different blood cell types [61] and no significant differences were found 
for the blood cell types for HRO-related analysis (Table S3) and, in the case of age-related analysis,  
we have included the estimated T cell (CD8+), T cell (CD4+), and B cell levels as covariates. The 
expression analyses were performed only in one of the two Spanish populations. In addition, the 
association analysis between age and DNA methylation has been focused on middle-aged subjects. 
Another limitation of this work would be the lack of children, youth and elderly subjects to replicate 
the age-related associations. However, this research is an initial study that enables the extrapolation of 
these findings to other populations. Moreover, the larger strength of the present work is that the results 
(associations between DNA methylation and age or the measures of HRO) are independent of gender; 
the selected CpG sites identified in the age and HRO-related analyses were significant in both cohorts 
and in the pooled population, and after controlling for several covariates besides gender. Moreover, the 
experimental design of the current work includes a dual approach in the same cells (the combination of 
DNA methylation and gene expression microarrays) for the search of HRO biomarkers. It also uses  
a type of biological sample (WBC) very easy to obtain and non-invasive. 
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3. Experimental Section 
3.1. Subjects and Study Protocol 
The current analysis was conducted within a subsample of 48 obese adults (48 ± 10 years old;  
BMI 36.2 ± 3.8 kg/m2; 46.8% female) that participated in the RESMENA (Metabolic Syndrome 
Reduction in Navarra) project which is a randomized controlled trial [62], and 25 subjects from the 
OBEPALIP study [63], which consisted on healthy women with an age range between 21 and 45 years 
old and a BMI between 27.5 and 36.40 kg/m2. The metabolic syndrome was diagnosed following the 
ATP III criteria [64]. Both studies were approved by the Ethics Committee of the University of 
Navarra. Consequently, all participants provided written, informed consent for participation in 
agreement with the Declaration of Helsinki (as revised in Hong Kong in 1989, in Edinburgh in  
2000 and in Korea in 2008). DNA and RNA were obtained through a clinical study approved by the 
Ethics Committee of University of Navarra (project identification code: 48/2009 on 27 November 
2009 (RESMENA) and 007/2009 on 26 February 2009 (OBEPALIP)) and appropriately registered at 
www.clinicaltrials.gov; NCT01087086 and NCT01138774. 
3.2. Procedures 
Anthropometric measurements (body weight, height and waist circumference) were conducted 
according to validated protocols, as previously described [62,63]. In order to evaluate HRO, the pooled 
population was assigned to two groups according to BMI classification and risk of obesity-related 
health problems [65]: “Low HRO” (Overweight (BMI: 25.0–29.9 kg/m2) and class 1 obesity (BMI: 
30.0–34.9 kg/m2)) and “High HRO” (class 2 obesity (BMI: 35.0–39.9 kg/m2) and class 3 obesity  
(BMI > 40 kg/m2)). 
Venous blood samples were drawn by venipuncture after a 12-h overnight fast. The EDTA—Plasma 
samples and WBC were separated from whole blood by centrifugation at 3500 rpm, 5 °C, 15 min 
(Model 5804R, Eppendorf, Humburg, Germany), and were frozen immediately at −80 °C until assay 
(WBC in buffy-coat with and without TRIzol reagent). 
3.3. DNA Isolation and DNA Methylation Analysis 
Genomic DNA was isolated from WBC by using the MasterPureTM DNA Purification Kit  
(Epicentre Biotechnologies, Madison, WI, USA) according to the manufacturer’s instructions. DNA 
was quantified using the PicoGreen® dsDNA Quantitation reagent (Invitrogen, Carlsbad, CA, USA).  
Bisulfite modification of 500 ng genomic DNA was carried out using the EZ DNA methylation kit 
(Zymo Research, Orange, CA, USA) according to the manufacturer’s protocol. 
Bisulfite-treated genomic DNA was whole-genome amplified, hybridized to Infinium Human 
Methylation 450K BeadChips (Illumina, San Diego, CA, USA) and scanned using the Illumina 
iScanSQ platform. The intensity of the images was extracted with the GenomeStudio Methylation 
Software Module (v 1.9.0, Illumina, San Diego, CA, USA). β-Values were computed using the 
formula β-Value = M/(U + M) where M and U are the raw “methylated” and “unmethylated” signals, 
respectively. β-Values were corrected for type I and type II bias using the peak-based correction. The 
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data were normalized in R using a categorical Subset Quantile Normalization method (SQN) and 
probes associated with X and Y chromosomes were filtered out using the pipeline developed by 
Touleimat and Tost [66]. Probes containing Single Nucleotide Polymorphisms (SNPs) with a minor 
allele frequency (MAF) <0.001 in Iberian population and probes hybridizing multiple genomic 
locations (19,835) [67] were removed from the analysis. A total of 358,639 CpG sites were used in 
order to identify CpG sites associated with age and HRO. Moreover, we performed an additional 
analysis to estimate the variation explained due to different cell types [61] and no significant 
differences were found for blood cell types for HRO-related analysis (Table S3). However, the T cell 
(CD8+), T cell (CD4+) and B cell coefficients for age were significant, so these estimated cell types 
were included in the adjustment for age (Table S3). The limma package [68] for the R statistical 
software was used to compute a linear regression (for age outcome) or moderated F-statistic (for HRO) 
adjusted by the effect of confounding factors, such as gender, smoking, metabolic syndrome, the 
research group that made each study, and batch effect and T cell (CD8+), T cell (CD4+) and B cells for 
age-related analysis. Also, the age-cohort and HRO-cohort interaction were taken into consideration. 
Raw p values were adjusted using the Benjamini-Hochberg procedure [69] and an False Discovery 
Rate (FDR) cut-off of 0.05 for the age-related analyses and p-value cut-off of 0.01 in combination  
with methylation differences of 10% in the HRO-related analyses were used as statistical  
significant threshold. 
3.4. Gene Ontology (GO) Analysis 
Gene Ontology (GO) was used to investigate the biological relevance of the CpG sites that were 
associated with age or HRO [70]. GO annotations of genes were obtained from the Locus Link 
database of NCBI (http://www.ncbi.nlm.nih.gov/). 
3.5. Gene Expression Analysis 
A total of 24 RNAs were purified from WBC of the RESMENA study by using the TRIzol RNA 
isolation protocol (Life technologies, Foster City, CA, USA) and the integrity of isolated RNA was 
evaluated with the Experion chip electrophoresis unit (Bio-Rad Laboratories, Munich, Germany) 
following the manufacturer’s instructions. In all samples we evaluated the RNA quality indicator 
number (RQI), which was considered optimal when ranging from 7.9 to 10. A total of 500 ng of 
starting material was used as input for the Illumina TotalPrep Amplification Kit protocol (Life 
Technologies, Foster City, CA, USA). 
Array-based gene expression analysis was performed with the Whole-Genome Assay technology 
(Illumina, San Diego, CA, USA). Labeled sample cRNA was hybridized to HumanHT-12 v4 
Expression BeadChip Kit (Illumina, San Diego, CA, USA) and scanned using the Illumina HiScan™ 
SQ platform. The intensity of the images was extracted with the GenomeStudio Gene Expression 
Software Module (v1.9.0, Illumina, San Diego, CA, USA). 
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3.6. Statistical Methods 
Data are expressed as means (standard deviations, SD), except as otherwise indicated. The 
characteristics of participants according to the two studies and HRO were compared. Differences in 
continuous values in Low versus High HRO subjects were performed by the Student’s t-test. 
Categorical variables were analyzed by χ2 test. Spearman correlations were fitted to evaluate the 
potential correlations of DNA methylation with age and expression levels. In addition, multiple linear 
regression models were performed to analyze the prediction of BMI (outcome) for selected CpG sites 
from HRO-related analysis adjusted by age, gender, smoking, metabolic syndrome, the research group 
that made each study, and batch effect. For stringency, only a p-value <0.05 was considered for 
analyses. Statistical analyses were performed using SPSS Statistics 19 software package (SPSS Inc., 
IBM, Somers, NY, USA). 
4. Conclusions 
As a conclusion, we have been able to replicate several findings from previous studies in two 
different Spanish cohorts, supporting an important role of DNA methylation in the age-related 
regulation of gene expression. We have described a significant influence of age on DNA methylation 
and mRNA levels of different genes in WBC (i.e., ELOV2, HOXC4 and PI4KB) and found, on a trend 
level, novel associations between DNA methylation and measures of HRO in genes like GPR133 and 
ITGB5. These data reinforce the idea that epigenetic variation has an important impact on aging and 
HRO. These results are a first step in understanding the modifications of the epigenome (and gene 
expression) in relation to age- and BMI-related health outcomes. However, further studies on the 
relevance of these and other CpG sites in relation to age and HRO should be performed. 
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